LLY stock forecast, quote, news & analysis

Key Takeaways

• Eli Lilly shares traded near $1,216 as of early July 2026, close to the 52-week high of $1,249.45, reflecting approximately 5.8% appreciation over the trailing 30 days.
• Q1 2026 revenue surged 55.5% year-over-year to $19.8 billion, with Mounjaro and Zepbound generating roughly $12.8 billion in combined global sales.
• The Medicare GLP-1 Bridge program launched July 1, 2026, making Zepbound and the oral pill Foundayo available to eligible beneficiaries for as little as $50 per month, potentially unlocking an estimated 20 million-patient market.
• Multiple Wall Street firms—including JPMorgan, RBC Capital, Truist Securities, and Cantor Fitzgerald—raised price targets in recent weeks, with targets now ranging from $1,250 to $1,500.
• Q2 2026 earnings are scheduled for August 5, with consensus expectations for another beat-and-raise quarter centered on continued GLP-1 prescription growth.
• Longer-term risks include Sandoz's ANDA filings for generic tirzepatide and mounting pricing pressure across the incretin category.

Current Market Snapshot

Eli Lilly and Company (NYSE: LLY) continues to command attention as the world's most valuable pharmaceutical company, with a market capitalization of approximately $1.15 trillion. The stock has climbed roughly 59% over the past twelve months and remains within striking distance of all-time highs. Trading at around $1,216, LLY carries a forward price-to-earnings ratio near 33x, reflecting elevated investor expectations for sustained growth from the company's cardiometabolic franchise. Broader healthcare sector sentiment has been supported through mid-2026 by sector rotation dynamics and expectations of strong second-quarter biopharma results. With 23 Buy ratings, four Holds, and a consensus Moderate Buy, Wall Street remains overwhelmingly constructive, though some analysts caution that valuation leaves limited room for disappointment heading into the August earnings report.

Eli Lilly and Company (LLY) Business Overview and Competitive Position

Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly is a global pharmaceutical company that researches, develops, manufactures, and commercializes medicines across multiple therapeutic areas. The company's modern growth story is anchored by its incretin portfolio, headlined by Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity. The April 2026 FDA approval of Foundayo (orforglipron), the only once-daily oral GLP-1 pill without food or water restrictions, further expanded Lilly's leadership in metabolic health. Beyond cardiometabolic medicine, the company's pipeline includes Omvoh for ulcerative colitis and Crohn's disease, Jaypirca for mantle cell lymphoma and chronic lymphocytic leukemia, Ebglyss for atopic dermatitis, and Kisunla for early symptomatic Alzheimer's disease. With 42 active Phase III programs and over $20 billion in biotech acquisitions announced in 2026, Lilly maintains one of the deepest late-stage pipelines in the industry. Its primary GLP-1 competitor remains Novo Nordisk (NVO).

Recent Developments Driving LLY

A wave of bullish analyst activity has reinforced investor confidence. In early July, RBC Capital raised its LLY price target to $1,500 with an Outperform rating, while JPMorgan lifted its target to $1,400, citing strong international Mounjaro momentum and steady U.S. Zepbound demand. Truist Securities raised its target to $1,370 and expects a second-quarter beat and guidance raise. Cantor Fitzgerald similarly boosted its target to $1,350. On the regulatory front, the July 1 Medicare GLP-1 Bridge program represents a landmark expansion of obesity drug coverage, with Zepbound and Foundayo now accessible to millions of Medicare Part D beneficiaries. In Canada, Lilly's eczema treatment Ebglyss received a positive recommendation from Canada's Drug Agency, and in Europe, the EMA's CHMP issued a positive opinion on Jaypirca for chronic lymphocytic leukemia. China-focused developments included Innovent Biologics securing exclusive Verzenios commercialization rights in mainland China. Offsetting these positives, Tampa General Hospital filed suit against Lilly over pulled 340B drug discounts, and Sandoz submitted ANDA applications for generic tirzepatide. Truist also noted that early Foundayo prescription growth has been slower than anticipated, though the firm maintains high conviction in the oral pill's long-term potential.

Trending AI Robots

For traders seeking a data-driven approach to navigating stocks like Eli Lilly, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of bots trading across thousands of tickers, spanning diverse strategies, timeframes, and performance profiles. The Trending section highlights only those bots demonstrating top-tier relevance and performance metrics, providing a streamlined view for investors who want to complement their own research with algorithmic insights. Whether the market favors momentum, mean reversion, or breakout strategies, these AI-driven tools adapt to shifting conditions. Explore the Trending AI Robots page to see which strategies are currently generating the strongest signals.

2026 Outlook and What Investors Should Watch

The near-term focus for LLY is the Q2 2026 earnings release on August 5, where analysts expect sales of roughly $20.7 billion and another potential guidance raise from the current full-year revenue range of $82 billion to $85 billion. Key metrics to monitor include U.S. Zepbound and Mounjaro prescription trends, Foundayo launch uptake and PBM coverage expansion, and international Mounjaro growth as new reimbursement agreements take effect. Later in 2026, Lilly plans to submit retatrutide—its triple-agonist GLP-1/GIP/glucagon candidate—for regulatory approval in obesity and knee osteoarthritis, a milestone that could meaningfully expand the addressable patient population. The Investment Community Meeting scheduled for December 7, 2026, may provide updated long-term growth targets. Risks include Sandoz's generic tirzepatide challenge, employer-driven reductions in obesity drug coverage, and continued pricing headwinds that management has flagged in the low-to-mid-teens percentage range. While Lilly's competitive moat remains wide, execution across the Foundayo launch and retatrutide regulatory pathway will be critical in sustaining investor confidence at current valuation levels.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.